Alnylam Pharmaceuticals Inc. reported earnings of -$16.889 million in Q2, a significant improvement from -$276.024 million in the same period last year. EPS also improved to -$0.13 from -$2.21. Adjusted earnings were $73.766 million or $0.56 per share. Analysts had projected earnings of -$1.08 per share. Revenue saw a substantial increase to $659.825 billion in Q2 from $318.754 billion in the same period last year.

Read more at Nasdaq: Alnylam Pharmaceuticals Inc. Q2 Earnings Summary